Health and economic burden associated with 15-valent pneumococcal conjugate vaccine serotypes in Korea and Hong Kong

Use of pneumococcal conjugate vaccines (PCVs) has greatly reduced the incidence of invasive pneumococcal disease (IPD). V114 (VAXNEUVANCE™, Merck Sharp & Dohme Corp. a subsidiary of Merck & Co. Inc. Kenilworth, NJ, USA) is a 15-valent PCV currently approved in adults in the United States, co...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohanty, Salini, Hu, Tianyan, Yang, GyongSeon, Khan, Tsz K, Owusu-Edusei, Kwame, Sukarom, Isaya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Pneumococcal – Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9196648/
https://www.ncbi.nlm.nih.gov/pubmed/35420975
http://dx.doi.org/10.1080/21645515.2022.2046433

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9196648/
https://www.ncbi.nlm.nih.gov/pubmed/35420975
http://dx.doi.org/10.1080/21645515.2022.2046433

Ejemplares similares